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Abstract
Background: Whereas evidence supporting the diagnostic value of cardiovascular magnetic resonance (CMR) has
increased, there exists significant worldwide variability in the clinical utilization of CMR. A recent study
demonstrated that CMR is represented in the majority of European Society for Cardiology (ESC) guidelines, with a
large number of specific recommendations in particular regarding coronary artery disease. To further investigate the
gap between the evidence and clinical use of CMR, this study analyzed the role of CMR in the guidelines of the
American College of Cardiology (ACC) and American Heart Association (AHA).
Methods: Twenty-four AHA/ACC original guidelines, updates and new editions, published between 2006 and 2017,
were screened for the terms “magnetic”, “MRI”, “CMR”, “MR” and “imaging”. Non-cardiovascular MR examinations
were excluded. All CMR-related paragraphs and specific recommendations for CMR including the level of evidence
(A, B, C) and the class of recommendation (I, IIa, IIb, III) were extracted.
Results: Twelve of the 24 guidelines (50.0%) contain specific recommendations regarding CMR. Four guidelines (16.
7%) mention CMR in the text only, and 8 (33.3%) do not mention CMR. The 12 guidelines with recommendations
for CMR contain in total 65 specific recommendations (31 class-I, 23 class-IIa, 6 class-IIb, 5 class-III). Most
recommendations have evidence level C (44/65; 67.7%), followed by level B (21/65; 32.3%). There are no level A
recommendations. 22/65 recommendations refer to vascular imaging, 17 to congenital heart disease, 8 to
cardiomyopathies, 8 to myocardial stress testing, 5 to left and right ventricular function, 3 to viability, and 2 to
valvular heart disease.
Conclusions: CMR is represented in two thirds of the AHA/ACC guidelines, which contain a number of specific
recommendations for the use of CMR. In a simplified comparison with the ESC guidelines, CMR is less represented
in the AHA/ACC guidelines in particular in the field of coronary artery disease.
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Background
The body of evidence supporting the beneficial utilization
of cardiovascular magnetic resonance (CMR) has grown
significantly over the last decade [1, 2]. A recent analysis
exhibited that CMR is already incorporated into 88% of
the guidelines published by the European Society of Cardi-
ology, in many as specific recommendations, and in most
at least by mention in the text passages [3]. Hence, CMR
commonly plays a role in evidence based diagnostic and
therapeutic pathways, and can even be considered
mandatory in a number of clinical scenarios. However, in
the experience of the authors, the integration of CMR into
clinical medicine appears to still be limited relative to the
growing evidence supporting its benefits. This discrepancy
may be attributed to a number of factors, such as limited
access to scanners equipped for CMR, lack of people with
the necessary skills to run and interpret a CMR study,
relatively high costs, competing diagnostic modalities, and
inadequate reimbursement. The guidelines published by
the American Heart Association (AHA) and the American
College of Cardiology (ACC) are often used as the basis
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for clinical decision making and therefore can have a high
impact on utilization of technology such as CMR. This
analysis systematically summarizes the representation of
CMR in the AHA/ACC guidelines to stimulate the discus-
sion about future needs for training, distribution of equip-
ment, and reimbursement of CMR worldwide.
Methods
All AHA/ACC guidelines published between 2006 and
June 2017 and listed on the AHA and ACC websites
were collected (Table 1). If more than one guideline for
the same topic was published during this period, the
most recent was included in the analysis. If a guideline
was updated, both the full guideline and the update were
analyzed in combination. The documents were screened
for the terms “magnetic”, “MRI”, “CMR”, “MR” and “im-
aging”. MRI in the context of non-cardiovascular exami-
nations, such as brain MRI, was not included. The main
conclusions were extracted, and if available, the class of
recommendation and the level of evidence were given.
The class of recommendation (i.e., the strength of the
recommendation) encompasses the anticipated magni-
tude and certainty of benefit in proportion to risk
(Table 2). The level of evidence rates evidence on the
basis of the type, quality, quantity, and consistency of
data from clinical trials and other reports (Table 3) [4].
Whereas recent guidelines separate levels B and C into
sublevels, earlier guidelines did not. In this analysis, the
level as provided in each guideline is given. The number
in parenthesis behind the citation provides the page
number of the full text guideline. If a recommendation
refers to “imaging” in general, it was registered only if
the context included CMR. This analysis was performed
twice for every guideline to assure that no relevant infor-
mation was missed. The absolute number of recommen-
dations was then summarized. The guidelines are listed
in chronologic order beginning with the most recent.
Only USA-guidelines published by the AHA and ACC
were included; AHA/ACC position statements, and
guidelines published by other organizations, were not in-
cluded to guarantee consistency.
Results
In total 24 AHA/ACC guidelines were analyzed. For five
guidelines, more recent updates were included in a com-
bined analysis with the full guidelines (heart failure update
2017 and 2016 [5, 6], valve disease update 2017 [7], stable
ischemic heart disease update 2014 [8], device-based ther-
apy of cardiac rhythm abnormalities update 2012 [9]).
There is one update from 2015 incorporating the previous
STEMI and PCI guidelines [10–12]. In this case, all three
documents were analyzed together, and the guidelines
were counted as two separate cases. Two updates on sec-
ondary prevention were published during the inclusion
period (2011 and 2006 [13, 14]), but no explicit original
guideline. Both updates were analyzed and counted as one
guideline. The “Guidelines on perioperative cardiovascular
evaluation and care for non-cardiac surgery” were pub-
lished twice (2014 and 2007 [15, 16]), but only the more
recent version entered the quantitative analysis.
Of the 24 analyzed AHA/ACC guidelines, 12 (50.0%)
contain specific recommendations regarding the use of
CMR (Table 1). Four guidelines (16.7%) principally men-
tion scenarios in which CMR may be used, but without
giving specific recommendations. Eight guidelines
(33.3%) do not mention CMR at all. (Fig. 1).
The 12 guidelines with recommendations regarding the
use of CMR contain in total 65 specific recommendations.
These are 31 class-I recommendations, 23 class-IIa
recommendations, 6 class-IIb recommendations and 5
class-III recommendations (Fig. 1). The 5 class-III
recommendations stem from the guidelines concern-
ing lower peripheral artery disease (n = 1) [4], stable
ischemic heart disease (n = 3) [8, 17], and risk assess-
ment in asymptomatic adults (n = 1) [18].
Most of the CMR recommendations have evidence level
C (44/65; 67.7%), followed by level B (21/65; 32.3%). No
CMR recommendations have evidence level A.
The four guidelines that contained the most recom-
mendations for CMR, were the guidelines on adults with
congenital heart disease (n = 17) [19], extracranial ca-
rotid and vertebral artery disease (n = 9) [20], thoracic
aortic disease (n = 8) [21], and stable ischemic heart dis-
ease (n = 8) [8, 17].
Twenty-two of the 65 recommendations refer to vas-
cular imaging, 17 recommendations refer to congenital
heart disease, 8 to myocardial stress testing, 8 to cardio-
myopathies, 5 to LV and RV function assessment, 3 to
viability and 2 to valvular heart disease (Fig. 1).
Table 4 lists the 65 recommendations categorized by
clinical scenario and diagnosis (following the style of the
ESC guideline summary [3]).
 2017 ACC/AHA/HFSA Focused Update of the 2013
ACCF/AHA Guideline for the Management of
Heart Failure [5]
 2016 ACC/AHA/HFSA Focused Update on New
Pharmacological Therapy for Heart Failure: An
Update of the 2013 ACCF/AHA Guideline for the
Management of Heart Failure [6]
 2013 ACCF/AHA Guideline for the Management of
Heart Failure - A Report of the American College of
Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines [22]
The most recent full AHA/ACC guideline regarding
heart failure was published in 2013 and updated in 2016
and 2017. In the 2013 full version, under the topic
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“Initial and serial evaluation of the heart failure patient”,
specific recommendations for the use of CMR are de-
fined, in particular regarding assessment of LV function,
perfusion and viability (Table 5). CMR is additionally
mentioned as an alternative to echocardiography, as
CMR “assesses LV volume and EF measurements at least
Table 1 List of AHA/ACC guidelines used for the analysis. +++ = guideline contains specific recommendations regarding the use of
CMR; ++ = guideline mentions scenarios in which CMR may be used, but without giving any specific recommendation;
+ = guideline does not mention CMR at all
Nr. Title Year Role of
CMR
I IIa IIb III
1 ▪ ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure [5]
▪ ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013
ACCF/AHA Guideline for the Management of Heart Failure [6]
▪ ACCF/AHA Guideline for the Management of Heart Failure [22]
2017
2016
2013
+++ 0 2 2 0
2 ▪ AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular
Heart Disease [7]
▪ AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease [23]
2017
2014
+++ 5 0 1 0
3 ▪ ACC/AHA/HRS Guideline for Evaluation and Management of Patients With Syncope [24] 2017 +++ 0 1 1 0
4 ▪ AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease [4] 2016 +++ 1 0 0 1
5 ▪ ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia [25] 2015 +
6 ▪ ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-
Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary
Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction [10]
▪ ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction [11]
2015
2013
+
7 ▪ ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention [12] 2011 ++
8 ▪ ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing
Noncardiac Surgery [15]
▪ ACC/AHA Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery [16]
2014
2007
++
9 ▪ ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of
Patients With Stable Ischemic Heart Disease [8]
▪ ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable
Ischemic Heart Disease [17]
2014
2012
+++ 1 4 0 3
10 ▪ AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes [26] 2014 +++ 1 0 0 0
11 ▪ AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation [27] 2014 ++
12 ▪ AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults [28] 2013 +
13 ▪ AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk [29] 2013 +
14 ▪ ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults [30]
2013 +
15 ▪ ACC/AHA Guideline on the Assessment of Cardiovascular Risk [31] 2013 +
16 ▪ ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based
Therapy of Cardiac Rhythm Abnormalities [9]
▪ ACC/AHA/HRS Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities [32]
2012
2008
++
17 ▪ ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy [33] 2011 +++ 2 1 3 0
18 ▪ ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery [34] 2011 +
19 ▪ AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other
Atherosclerotic Vascular Disease: 2011 Update [13]
▪ AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular
Disease: 2006 Update [14]
2011
2006
+
20 ▪ ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/ SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of
Patients With Extracranial Carotid and Vertebral Artery [20]
2011 +++ 4 4 1 0
21 ▪ ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients
With Thoracic Aortic Disease [21]
2010 +++ 3 5 0 0
22 ▪ ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults [18] 2010 +++ 0 0 0 1
23 ▪ ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease [19] 2008 +++ 14 2 1 0
24 ▪ ACC/AHA/ESC Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of
Sudden Cardiac Death [35]
2006 +++ 0 1 0 0
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as accurately as echocardiography” (page 19). Further-
more, its potential to provide “additional information
about myocardial perfusion, viability, and fibrosis can
help identify heart failure etiology and assess prognosis”
(page 19) is highlighted. Finally, the use of CMR in
known or suspected congenital heart diseases is indi-
cated as “CMR provides high anatomical resolution of all
aspects of the heart and surrounding structure” (page 19).
Under the heading “Cardiac structural abnormalities and
other causes of heart failure”, CMR is recommended in
subjects with known or suspected cardiac sarcoidosis, as
CMR “can identify cardiac involvement with patchy areas
of myocardial inflammation and fibrosis” (page 14).
 2017 AHA/ACC Focused Update of the 2014 AHA/
ACC Guideline for the Management of Patients
With Valvular Heart Disease [7]
 2014 AHA/ACC Guideline for the Management of
Patients With Valvular Heart Disease [23]
In patients with suspected valvular heart disease,
echocardiography is the cornerstone of the diagnos-
tic algorithm. The guideline adds that generally
“Other ancillary testing such as transesophageal
echocardiography (TEE), computed tomography (CT) or
cardiac magnetic resonance (CMR) imaging, stress testing,
and diagnostic hemodynamic cardiac catheterization may
Table 2 Class (Strength) of Recommendation [4]
Class of recommendation Definition Suggested phrases for writing recommendations
Class I (strong) Benefit >> > Risk • is recommended
• is indicated / useful / effective / beneficial
• should be performed / administered / other
• Comparative-Effectiveness phrases:
− Treatment / strategy A is recommended / indicated
in preference to treatment B
− Treatment A should be chosen over treatment B
Class IIa (Moderate) Benefit > > Risk • Is reasonable
• Can be useful / effective / beneficial
• Comparative-Effectiveness phrases
− Treatment / strategy A is probably recommended /
indicated in preference to treatment B
− It is reasonable to choose treatment A over treatment B
Class IIb (Weak) Benefit ≥ Risk • May / might be reasonable
• May / might be considered
• Usefulness / effectiveness is unknown / unclear / uncertain
or not well established
Class III: No benefit (Moderate) Benefit = Risk • Is not recommended
• Is not indicated / useful / effective / beneficial
• Should not be performed / administered / other
Class III: Harm (Strong) Risk > Benefit • Potentially harmful
• Causes harm
• Associated with excess morbidity / mortality
• Should not be performed / administered / other
Table 3 Level of Evidence [4]
Level Definition
Level A • High quality evidence from more than 1 randomized controlled trial
• Meta-analyses of high-quality randomized controlled trials
• One or more randomized controlled trial corroborated by high-quality registry studies
Level B-R (randomized) • Moderate-quality evidence from 1 or more randomized controlled trial
• Meta-analyses of moderate-quality randomized controlled trials
Level B-NR (nonrandomized) • Moderate-quality evidence from 1 or more well-designed well-executed nonrandomized
studies, observational studies, or registry studies
• Meta-analyses of such studies
Level C-LD (limited data) • Randomized or nonrandomized observational or registry studies with limitations of
design or execution
• Meta-analyses of such studies
• Physiological or mechanistic studies in human subjects
Level C-EO (expert opinion) • Consensus of expert opinion based on clinical experience
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be required to determine the optimal treatment for a pa-
tient with valvular heart disease” (page 7).
Specifically, in aortic stenosis, “CMR imaging shows
promise for evaluation of severity of aortic stenosis, but is
not widely available” (page 17). In aortic regurgitation,
“CMR imaging provides accurate measures of regurgitant
volume and regurgitant fraction... as well as assessment of
aortic morphology, LV volume, and LV systolic function.
In addition to its value in patients with suboptimal echo-
cardiographic data, CMR is useful for evaluating patients
in whom there is discordance between clinical assessment
and severity of aortic regurgitation by echocardiography.
CMR measurement of regurgitant severity is less variable
than echocardiographic measurement” (page 29). This ap-
proach is expressed as a Class I, Level B-recommendation
(Table 6). In subjects with aortic regurgitation and chronic
aortic disease, “CMR imaging is useful ..., but is rarely used
in unstable patients with suspected dissection” (page 27).
For the subset of patients with bicuspid aortic valve dis-
ease, the guideline defines several specific recommenda-
tions about the use of CMR to assess the thoracic aorta
(Table 6). In this context, the guideline states that “Mag-
netic resonance angiography or chest CT angiography
provide accurate diameter measurements when aligned
perpendicular to the long axis of the aorta. Advantages of
magnetic resonance angiography and CT angiography
compared with TTE include higher spatial (but lower tem-
poral) resolution and the ability to display a 3D recon-
struction of the entire length of the aorta”(page 33).
Furthermore, the guideline emphasizes that “Magnetic
resonance angiography imaging is preferred over CT angi-
ography imaging, when possible, because of the absence of
ionizing radiation exposure in patients who likely will have
multiple imaging studies over their lifetime” (page 33).
In mitral regurgitation (MR), “in cases where TTE
image quality is poor, CMR may be of value in MR
evaluation. CMR produces highly accurate data on LV
volumes, RV volumes, and LVEF, and an estimation of
MR severity, but outcome data using CMR volumes is
pending. CMR is less helpful in establishing mitral
pathoanatomy” (pages 43–44; Table 6). Furthermore,
“Three-dimensional echocardiography, strain imaging,
or CMR may add more accurate assessment of the LV
response in the future” (page 43).
In tricuspid regurgitation, “Both CMR and real-time
3D echocardiography may provide more accurate assess-
ment of right ventricular volumes and systolic function,
as well as annular dimension and the degree of leaflet
tethering. CMR may be the ideal modality in young
asymptomatic patients with severe tricuspid regurgita-
tion to assess initial and serial measurements of right
ventricular size and systolic function” (Table 6).
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Fig. 1 Panel a Categorization of the 24 analyzed AHA/ACC guidelines regarding the role of CMR. Panel b Distribution of the 65 specific
recommendations for CMR in the 24 AHA/ACC guidelines regarding “class of recommendations” and “level of evidence”. Panel c Categorization
of the 65 specific recommendations in the 24 AHA/ACC guidelines regarding the diagnostic target
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Table 4 Summary of clinical scenarios / diagnosis groups, where the AHA/ACC guidelines make recommendations regarding CMR
Class Level Guideline
Suspected / stable coronary artery disease
Noninvasive imaging to detect myocardial ischemia and viability is reasonable in heart failure and
coronary artery disease
IIa C Heart failure [5, 6, 22]
Noninvasive imaging (stress nuclear/positron emission tomography, CMR, or stress echocardiography),
cardiac CT angiography, or cardiac catheterization, including coronary arteriography, is useful to establish
etiology of chronic secondary MR (stages B to D) and/or to assess myocardial viability, which in turn may
influence management of functional MR.
I C Valve disease [7, 23]
Pharmacological stress with CMR can be useful for patients with an intermediate to high pretest
probability of obstructive ischemic heart disease, who have an uninterpretable ECG and at least
moderate physical functioning or no disabling comorbidity.
IIa B Stable CAD [8]
Pharmacological stress CMR is reasonable for patients with an intermediate to high pretest probability of
ischemic heart disease, who are incapable of at least moderate physical functioning or have disabling
comorbidity.
IIa B Stable CAD [8]
Echocardiography, radionuclide imaging, CMR, and cardiac CT are not recommended for routine
assessment of LV function in patients with a normal ECG, no history of myocardial infarction, no
symptoms or signs suggestive of heart failure, and no complex ventricular arrhythmias.
III C Stable CAD [8]
Routine reassessment (<1 year) of LV function with technologies such as echocardiography, radionuclide
imaging, CMR, or cardiac CT is not recommended in patients with no change in clinical status and for
whom no change in therapy is contemplated.
III C Stable CAD [8]
CMR with pharmacological stress is reasonable for risk assessment in patients with stable ischemic heart
disease who are able to exercise to an adequate workload but have an uninterpretable ECG.
IIa B Stable CAD [8]
Pharmacological stress imaging (nuclear MPI, echocardiography, or CMR) or CCTA is not recommended
for risk assessment in patients with stable ischemic heart disease who are able to exercise to an
adequate workload and have an interpretable ECG.
III C Stable CAD [8]
Pharmacological stress CMR is reasonable for risk assessment in patients with stable ischemic heart
disease who are unable to exercise to an adequate workload regardless of interpretability of ECG.
IIa B Stable CAD [8]
Acute coronary syndrome
Imaging with ventriculography, echocardiography, or magnetic resonance imaging should be performed
to confirm or exclude the diagnosis of stress (Takotsubo) cardiomyopathy.
I B NSTEMI [26]
Before coronary revascularization
Viability assessment is reasonable before revascularization in heart failure patients with coronary artery
disease
IIa B Heart failure [5, 6, 22]
Either exercise or pharmacological stress with imaging (nuclear MPI, echocardiography, or CMR) is
recommended for risk assessment in patients with stable ischemic heart disease, who are being
considered for revascularization of known coronary stenosis of unclear physiological significance.
I B Stable CAD [8]
Heart failure
Radionuclide ventriculography or MRI can be useful to assess LVEF and volume IIa C Heart failure [5, 6, 22]
MRI is reasonable when assessing myocardial infiltration or scar IIa B Heart failure [5, 6, 22]
Ventricular arrhythmia
MRI, cardiac computed tomography (CT), or radionuclide angiography can be useful in patients with
ventricular arrhythmias when echocardiography does not provide accurate assessment of LV and RV function
and/or evaluation of structural changes.
IIa B Ventricular
arrhythmias [35]
Hypertrophic cardiomyopathy
CMR imaging is indicated in patients with suspected HCM when echocardiography is inconclusive for
diagnosis.
I B HCM [33]
CMR imaging is indicated in patients with known HCM when additional information that may have an
impact on management or decision making regarding invasive management, such as magnitude and
distribution of hypertrophy or anatomy of the mitral valve apparatus or papillary muscles, is not adequately
defined with echocardiography.
I B HCM [33]
CMR imaging is reasonable in patients with HCM to define apical hypertrophy and/or aneurysm if
echocardiography is inconclusive.
IIa B HCM [33]
In selected patients with known HCM, when SCD risk stratification is inconclusive after documentation of
the conventional risk factors, CMR imaging with assessment of late gadolinium enhancement (LGE) may be
considered in resolving clinical decision making.
IIb C HCM [33]
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Table 4 Summary of clinical scenarios / diagnosis groups, where the AHA/ACC guidelines make recommendations regarding CMR
(Continued)
The usefulness of the following potential SCD risk modifiers is unclear but might be considered in selected
patients with HCM for whom risk remains borderline after documentation of conventional risk factors: CMR
imaging with LGE.
IIb C HCM [33]
Athlete’s heart
Extended monitoring (including MRI) can be beneficial for athletes with unexplained exertional syncope
after an initial cardiovascular evaluation.
IIa C-LD Syncope [24]
Storage disease
CMR imaging may be considered in patients with LV hypertrophy and the suspicion of alternative
diagnoses to HCM, including cardiac amyloidosis, Fabry disease, and genetic phenocopies such as LAMP2
cardiomyopathy.
IIb C HCM [33]
Vascular disease
Aortic magnetic resonance angiography or CT angiography is indicated in patients with a bicuspid aortic
valve when morphology of the aortic sinuses, sinotubular junction, or ascending aorta cannot be assessed
accurately or fully by echocardiography. (Level of Evidence: C)
I C Valve disease [7, 23]
Serial evaluation of the size and morphology of the aortic sinuses and ascending aorta by
echocardiography, CMR, or CT angiography is recommended in patients with a bicuspid aortic valve and an
aortic diameter greater than 4.0 cm, with the examination interval determined by the degree and rate of
progression of aortic dilation and by family history. In patients with an aortic diameter greater than 4.5 cm,
this evaluation should be performed annually.
I C Valve disease [7, 23]
Duplex ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography (MRA)
of the lower extremities is useful to diagnose anatomic location and severity of stenosis for patients with
symptomatic peripheral artery disease in whom revascularization is considered
I B-NR Peripheral Artery
Disease [4]
Invasive and noninvasive angiography (ie, CTA, MRA) should not be performed for the anatomic assessment
of patients with asymptomatic peripheral artery disease.
III B-R Peripheral Artery
Disease [4]
In patients with acute, focal ischemic neurological symptoms corresponding to the territory supplied by the
left or right internal carotid artery, magnetic resonance angiography (MRA) or computed tomography
angiography (CTA) is indicated to detect carotid stenosis when sonography either cannot be obtained or
yields equivocal or otherwise nondiagnostic results.
I C Carotid and vertebral
artery [20]
When an extracranial source of ischemia is not identified in patients with transient retinal or hemispheric
neurological symptoms of suspected ischemic origin, CTA, MRA, or selective cerebral angiography can be
useful to search for intracranial vascular disease.
IIa C Carotid and vertebral
artery [20]
When the results of initial noninvasive imaging are inconclusive, additional examination by use of another
imaging method is reasonable. In candidates for revascularization, MRA or CTA can be useful when results of
carotid duplex ultrasonography are equivocal or indeterminate.
IIa C Carotid and vertebral
artery [20]
When intervention for significant carotid stenosis detected by carotid duplex ultrasonography is planned,
MRA, CTA, or catheter-based contrast angiography can be useful to evaluate the severity of stenosis and to
identify intrathoracic or intracranial vascular lesions that are not adequately assessed by duplex
ultrasonography.
IIa C Carotid and vertebral
artery [20]
MRA without contrast is reasonable to assess the extent of disease in patients with symptomatic carotid
atherosclerosis and renal insufficiency or extensive vascular calcification.
IIa C Carotid and vertebral
artery [20]
When complete carotid arterial occlusion is suggested by duplex ultrasonography, MRA, or CTA in patients
with retinal or hemispheric neurological symptoms of suspected ischemic origin, catheter-based contrast
angiography may be considered to determine whether the arterial lumen is sufficiently patent to permit
carotid revascularization.
IIb C Carotid and vertebral
artery [20]
Noninvasive imaging by CTA or MRA for detection of vertebral artery disease should be part of the initial
evaluation of patients with neurological symptoms referable to the posterior circulation and those with
subclavian steal syndrome.
I C Carotid and vertebral
artery [20]
In patients whose symptoms suggest posterior cerebral or cerebellar ischemia, MRA or CTA is
recommended rather than ultrasound imaging for evaluation of the vertebral arteries.
I C Carotid and vertebral
artery [20]
Contrast-enhanced CTA, MRA, and catheter-based contrast angiography are useful for diagnosis of cervical
artery dissection.
I C Carotid and vertebral
artery [20]
Urgent and definitive imaging of the aorta using transesophageal echocardiogram, computed tomographic
imaging, or magnetic resonance imaging is recommended to identify or exclude thoracic aortic dissection in
patients at high risk for the disease by initial screening.
I B Thoracic aorta [21]
The initial evaluation of Takayasu arteritis or giant cell arteritis should include thoracic aorta and branch
vessel computed tomographic imaging or magnetic resonance imaging to inves- tigate the possibility of
aneurysm or occlusive disease in these vessels.
I C Thoracic aorta [21]
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Table 4 Summary of clinical scenarios / diagnosis groups, where the AHA/ACC guidelines make recommendations regarding CMR
(Continued)
For patients with isolated aortic arch aneurysms less than 4.0 cm in diameter, it is reasonable to reimage
using computed tomographic imaging or magnetic resonance imaging, at 12- month intervals, to detect
enlargement of the aneurysm.
IIa C Thoracic aorta [21]
For patients with isolated aortic arch aneurysms 4.0 cm or greater in diameter, it is reasonable to reimage
using computed tomographic imaging or magnetic resonance imaging, at 6-month intervals, to detect en
largement of the aneurysm.
IIa C Thoracic aorta [21]
For imaging of pregnant women with aortic arch, descending, or abdominal aortic dilatation, magnetic
resonance imaging (without gadolinium) is recommended over computed tomographic imaging to avoid
exposing both the mother and fetus to ionizing radiation. Transesophageal echocardiogram is an option for
imaging of the thoracic aorta.
I C Thoracic aorta [21]
Computed tomographic imaging or magnetic resonance imaging of the thoracic aorta is reasonable after a
Type A or B aortic dissection or after prophylactic repair of the aortic root/ ascending aorta.
IIa C Thoracic aorta [21]
Computed tomographic imaging or magnetic resonance imaging of the aorta is reasonable at 1, 3, 6, and
12 months postdissection and, if stable, annually thereafter so that any threatening enlargement can be
detected in a timely fashion.
IIa C Thoracic aorta [21]
If a thoracic aortic aneurysm is only moderate in size and remains relatively stable over time, magnetic
resonance imaging instead of computed tomographic imaging is reasonable to minimize the patient’s
radiation exposure.
IIa C Thoracic aorta [21]
MRI for detection of vascular plaque is not recommended for cardiovascular risk assessment in
asymptomatic adults.
III C Risk assessment [18]
Valvular heart disease
CMR is indicated in patients with moderate or severe AR (stages B, C, and D) and suboptimal
echocardiographic images for the assessment of LV systolic function, systolic and diastolic volumes, and
measurement of AR severity.
I B Valve disease [7, 23]
CMR is indicated in patients with chronic primary MR to assess LV and RV volumes, function, or MR severity
and when these issues are not satisfactorily addressed by TTE.
I B Valve disease [7, 23]
CMR or real-time 3D echocardiography may be considered for assessment of right ventricular systolic
function and systolic and diastolic volumes in patients with severe tricuspid regurgitation (stages C and D)
and suboptimal 2D echocardiograms.
IIb C Valve disease [7, 23]
Congenital heart disease
Diagnostic and interventional procedures, including imaging (ie, echocardiography, MRI, or CT, advanced
cardiac catheterization, and electrophysiology procedures for adults with complex and moderate CHD should
be performed in a regional ACHD center with appropriate experience in CHD and in a laboratory with
appropriate personnel and equipment. Personnel performing such procedures should work as part of a team
with expertise in the surgical and transcatheter management of patients with CHD.
I C Congenital heart
disease [19]
(In bicuspid aortic valve disease) MRI/CT can be beneficial to add important information about the anatomy
of the thoracic aorta.
IIa C Congenital heart
disease [19]
(In bicuspid aortic valve disease) MRI may be beneficial in quantifying aortic regurgitation when other data
are ambiguous or borderline.
IIb C Congenital heart
disease [19]
(In supravalvular aortic stenosis) TTE and/or TEE with Doppler and either MRI or CT should be performed to
assess the anatomy of the LVOT, the ascending aorta, coronary artery anatomy and flow, and main and
branch pulmonary artery anatomy and flow.
I C Congenital heart
disease [19]
Every patient with coarctation (repaired or not) should have at least 1 cardiovascular MRI or CT scan for
complete evaluation of the thoracic aorta and intracranial vessels.
I B Congenital heart
disease [19]
Evaluation of the coarctation repair site by MRI/CT should be performed at intervals of 5 years or less,
depending on the specific anatomic findings before and after repair.
I C Congenital heart
disease [19]
Patients with suspected supravalvular, branch, or peripheral pulmonary stenosis should have baseline
imaging with echocardiography-Doppler plus 1 of the following: MRI angiography, CT angiography, or
contrast angiography.
I C Congenital heart
disease [19]
(In congenital coronary anomalies of ectopic arterial origin) CT or MRA is useful as the initial screening
method in centers with expertise in such imaging.
I B Congenital heart
disease [19]
(In suspicion of a coronary arteriovenous fistula), if a continuous murmur is present, its origin should be
defined either by echocardiography, MRI, CT angiography, or cardiac catheterization.
I C Congenital heart
disease [19]
The evaluation of all ACHD patients with suspected pulmonary arterial hypertension should include
noninvasive assessment of cardiovascular anatomy and potential shunting, as detailed below: Diagnostic
cardiovascular imaging via TTE, TEE, MRI, or CT as appropriate.
I C Congenital heart
disease [19]
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 2017 ACC/AHA/HRS Guideline for the Evaluation
and Management of Patients With Syncope [24]
“Imaging modalities, including CT and MRI, are
usually reserved for selected patients presenting with
syncope, especially when other noninvasive means are
inadequate or inconclusive. These modalities offer su-
perior spatial resolution in delineating cardiovascular
anatomy (e.g., in patients with structural, infiltrative,
or congenital heart disease. ... MRI is useful when
there is a suspicion of ARVC or cardiac sarcoidosis”
(page 25). In athletes, “imaging may include echocar-
diography or MRI as required” (page 64). The specific
recommendations for CMR in patients with syncope
are shown in Table 7.
 2016 AHA/ACC Guideline on the management of
patients with lower extremity peripheral artery
disease [4]
This guideline contains two recommendations for
CMR under the heading “3.3. Imaging for anatomic as-
sessment” (Table 8). Furthermore, Fig. 1 in the guideline
(“Diagnostic testing for suspected peripheral artery dis-
ease”) and figure 2 in the guideline (“Diagnostic testing
for suspected critical limb ischemia”) include CMR as
part of the diagnostic algorithm.
For symptomatic patients with peripheral artery disease,
in whom revascularization is considered, additional im-
aging with duplex ultrasonography, CTA, or MRA is use-
ful to develop an individualized treatment plan. The
guidelines state, “all 3 of these noninvasive imaging
methods have good sensitivity and specificity as compared
with invasive angiography” (page 24). CMR is character-
ized by superior spatial resolution compared to ultra-
sound. The guideline also discusses the issue that
gadolinium contrast, used frequently in CMR angiog-
raphy studies, can confer risk of nephrogenic systemic
sclerosis in patients with advanced renal dysfunction.
Generally, the choice of the examination should be
determined in an individualized approach to the
Table 4 Summary of clinical scenarios / diagnosis groups, where the AHA/ACC guidelines make recommendations regarding CMR
(Continued)
Patients with tetralogy of Fallot should have echocardiographic examinations and/or MRIs performed by
staff with expertise in ACHD.
I C Congenital heart
disease [19]
Additional imaging with TEE, CT, or MRI, as appropriate, should be performed in a regional ACHD center to
evaluate the great arteries and veins, as well as ventricular function, in patients with prior atrial baffle repair
of d-TGA.
I B Congenital heart
disease [19]
Periodic MRI or CT can be considered appropriate to evaluate the anatomy and hemodynamics in more
detail in patients with prior arterial switch operation.
IIa C Congenital heart
disease [19]
(In congenitally corrected transposition of the great arteries), echocardiography-Doppler study and/or MRI
should be performed yearly or at least every other year by staff trained in imaging complex CHD.
I C Congenital heart
disease [19]
The following diagnostic evaluations are recommended for patients with congenitally corrected
transposition of the great arteries: ECG, chest x-ray, echocardiography-Doppler study, MRI, exercise testing.
I C Congenital heart
disease [19]
(In patients with prior repair of congenitally corrected transposition of the great arteries), echocardiography-
Doppler study and/or MRI should be performed yearly or at least every other year by staff trained in imaging
complex CHD.
I C Congenital heart
disease [19]
All patients with prior Fontan type of repair should have periodic echocardiographic and/or magnetic
resonance examinations performed by staff with expertise in ACHD.
I C Congenital heart
disease [19]
Syncope
Computed tomography (CT) or magnetic resonance imaging (MRI) may be useful in selected patients
presenting with syncope of suspected cardiac etiology.
IIb B-NR Syncope [24]
Class = class of recommendation
Level = level of evidence
NSTEMI = non-ST-elevation myocardial infarction
CAD = coronary artery disease
HCM = hypertrophic cardiomyopathy
Table 5 Recommendations for CMR in heart failure
Recommendations for non-invasive cardiac im-
aging in heart failure
Classa Levelb Page
Radionuclide ventriculography or MRI can be
useful to assess LVEF and volume
IIa C 18
Noninvasive imaging to detect myocardial
ischemia and viability is reasonable in heart failure
and coronary artery disease
IIa C 18
Viability assessment is reasonable before
revascularization in heart failure patients with
coronary artery disease
IIa B 18
MRI is reasonable when assessing myocardial
infiltration or scar
IIa B 18
aClass of recommendation
bLevel of evidence
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anatomic assessment for each patient, including risk-
benefit assessment of each study type (page 24).
Furthermore, the guideline emphasized that angiography,
either noninvasive or invasive, should not be performed for
the anatomic assessment of patients with peripheral artery
disease without leg symptoms because delineation of
anatomy will not change treatment for this population
(page 25), expressed as a III-B recommendation.
 2015 ACC/AHA/HRS Guideline for the
management of adult patients with supraventricular
tachycardia [25]
This guideline does not mention CMR.
 2015 ACC/AHA/SCAI Focused Update on Primary
Percutaneous Coronary Intervention for Patients
With ST-Elevation Myocardial Infarction: An Up-
date of the 2011 ACCF/AHA/SCAI Guideline for
Percutaneous Coronary Intervention and the 2013
ACCF/AHA Guideline for the Management of ST-
Elevation Myocardial Infarction [10]
 2013 ACCF/AHA Guideline for the Management of
ST-Elevation Myocardial Infarction [11]
 2011 ACCF/AHA/SCAI Guideline for Percutaneous
Coronary Intervention [12]
The 2015 update and the 2013 STEMI guideline do not
mention CMR. In the 2011 percutaneous coronary interven-
tion guideline, CMR is mentioned in the text as a diagnostic
tool to detect periprocedural myocardial infarction (page 40).
 2014 ACC/AHA Guideline on Perioperative
Cardiovascular Evaluation and Management of
Patients Undergoing Noncardiac Surgery [15]
 2007 ACC/AHA Guidelines on Perioperative
Cardiovascular Evaluation and Care for Noncardiac
Surgery [16]
Table 6 Recommendations for CMR in valvular heart disease
Classa Levelb Page
Aortic regurgitation
CMR is indicated in patients with moderate or severe AR (stages B, C, and D) and suboptimal echocardiographic images
for the assessment of LV systolic function, systolic and diastolic volumes, and measurement of AR severity.
I B 29
Bicuspid aortic valve disease
Aortic magnetic resonance angiography or CT angiography is indicated in patients with a bicuspid aortic valve when
morphology of the aortic sinuses, sinotubular junction, or ascending aorta cannot be assessed accurately or fully by
echocardiography.
I C 32
Serial evaluation of the size and morphology of the aortic si- nuses and ascending aorta by echocardiography, CMR, or CT
angiography is recommended in patients with a bicuspid aortic valve and an aortic diameter greater than 4.0 cm, with
the examination interval determined by the degree and rate of progression of aortic dilation and by family history. In
patients with an aortic diameter greater than 4.5 cm, this evaluation should be performed annually.
I C 33
Mitral regurgitation
CMR is indicated in patients with chronic primary MR to assess LV and RV volumes, function, or MR severity and when
these issues are not satisfactorily addressed by TTE.
I B 43
Noninvasive imaging (stress nuclear/positron emission tomog- raphy, CMR, or stress echocardiography), cardiac CT
angiography, or cardiac catheterization, including coronary arteriography, is useful to establish etiology of chronic
secondary MR (stages B to D) and/or to assess myocardial viability, which in turn may influence management of
functional MR.
I C 50
Tricuspid regurgitation
CMR or real-time 3D echocardiography may be considered for assessment of right ventricular systolic function
and systolic and diastolic volumes in patients with severe tricuspid regurgitation (stages C and D) and suboptimal
2D echocardiograms.
IIb C 54
aClass of recommendation
bLevel of evidence
Table 7 Recommendations for cardiac imaging in syncope
Recommendations for cardiac imaging in syncope Classa Levelb Page
Computed tomography (CT) or magnetic resonance imaging (MRI) may be useful in selected patients presenting with syncope
of suspected cardiac etiology.
IIb B-NR 25
Extended monitoring (including MRI) can be beneficial for athletes with unexplained exertional syncope after an initial
cardiovascular evaluation.
IIa C-LD 64
aClass of recommendation
bLevel of evidence
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In subjects undergoing non-cardiac surgery, the appro-
priate preoperative use of non-invasive stress testing is
discussed. There are several specific recommendations
in the guideline covering different clinical scenarios. The
only recommended stress (exercise or pharmacology)
tests with imaging are nuclear myocardial perfusion and
dobutamine stress echocardiography (pages 18–20). Re-
garding CMR it is stated, “There are insufficient data to
support the use of dobutamine stress magnetic reson-
ance imaging in preoperative risk assessment” (page 20).
Under the heading “future research directions”, the
document states, “Diagnostic cardiovascular testing con-
tinues to evolve, with newer imaging modalities being
developed, such as ... cardiac magnetic resonance im-
aging. The value of these modalities in preoperative
screening is uncertain and warrants further study” (page 35).
 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused
Update of the Guideline for the Diagnosis and
Management of Patients With Stable Ischemic Heart
Disease [8]
 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
Guideline for the Diagnosis and Management of
Patients With Stable Ischemic Heart Disease [17]
In the 2014 update, CMR is not mentioned. One of
the central aspects of the 2012 full guideline is the ap-
propriate use of noninvasive stress testing to assess cor-
onary artery disease. Nuclear perfusion imaging and
stress-echocardiography are generally regarded as first
choices; however, CMR is included both in the text and
in the diagnostic algorithms and in the specific recom-
mendations, underlying its increasing importance.
The guideline is separated into several parts, with the
first part focusing on the initial diagnosis of stable ische-
mic heart disease. Stress CMR is included both in figure 2
of the guideline (page 12) illustrating the diagnostic algo-
rithm, and in table 11 of the guideline (page 23) that sum-
marizes the recommendation level for all available
diagnostic tests. Two specific recommendations for stress
CMR are expressed (Table 9). A subchapter (page 25)
summarizes the current evidence regarding the diagnostic
accuracy of pharmacological stress CMR wall motion /
perfusion imaging, and underlines the complementary in-
formation provided by late gadolinium enhancement scar
imaging. In addition, under the subheading “cost effective-
ness”, data from the EuroCMR registry are mentioned,
which provided evidence that “CMR can improve patient
management” by reducing the number of indicated coron-
ary angiographies (page 22). Finally, the idea of imaging
the coronary anatomy by CMR angiography is discussed
in a subchapter (page 26), pointing at the principal feasibil-
ity in studies, but also underlining its variable diagnostic
accuracy and limited widespread use. On page 21, poten-
tial limitations of CMR (claustrophobia, implanted devices,
nephrogenic systemic fibrosis) are mentioned.
A second part of the guideline deals with risk stratifica-
tion in known coronary artery disease. The comprehensive
information gained by CMR is pronounced: CMR “accur-
ately measures LV performance and provides insight into
myocardial and valvular structures. Use of delayed hyperen-
hancement techniques can identify otherwise undetected
scarred as well as viable myocardium.” (page 30). The use
of CMR to risk stratify subjects with coronary artery disease
is integrated both in figure 3 of the guideline (page 13) con-
taining the corresponding diagnostic algorithm, in table 12
of the guideline (page 31) that summarizes the recommen-
dation level for all diagnostic tests and in tables 20 and 21
of the guideline (page 77–78) that summarize the tests for
follow-up. Several scenarios where CMR is or is not recom-
mended are reflected in specific recommendations
(Table 10). A subchapter summarizes the evidence for
Table 8 Recommendations for CMR in peripheral artery disease
Recommendations for imaging for anatomic assessment Classa Levelb Page
Duplex ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography (MRA) of the lower
extremities is useful to diagnose anatomic location and severity of stenosis for patients with symptomatic peripheral artery
disease in whom revascularization is considered
I B-NR 24
Invasive and noninvasive angiography (ie, CTA, MRA) should not be performed for the anatomic assessment of patients with
asymptomatic peripheral artery disease.
III B-R 25
aClass of recommendation
bLevel of evidence
Table 9 Recommendations for CMR for the diagnosis of stable coronary artery disease
Diagnosis stable coronary artery disease Classa Levelb Page
Pharmacological stress with CMR can be useful for patients with an intermediate to high pretest probability of obstructive
ischemic heart disease, who have an uninterpretable ECG and at least moderate physical functioning or no disabling
comorbidity.
IIa B 22
Pharmacological stress CMR is reasonable for patients with an intermediate to high pretest probability of ischemic heart
disease, who are incapable of at least moderate physical functioning or have disabling comorbidity.
IIa B 24
aClass of recommendation
bLevel of evidence
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pharmacological stress CMR to gain prognostic informa-
tion (page 33). It concludes: 1. “A normal stress CMR study
with either vasodilator myocardial perfusion or inotropic
stress cine imaging is associated with a low annual rate of
cardiac death or myocardial infarction. 2. Detection of myo-
cardial ischemia... and LGE imaging of infarction appear to
provide complementary information. 3. An abnormal stress
CMR with evidence of ischemia is associated with elevated
likelihood of cardiac death or myocardial infarct”. Another
subchapter about “Future developments” (page 81) predicts
increasing use of CMR in stable coronary artery disease in
the future, being supported by upcoming technological de-
velopments, like image acquisition acceleration.
 2014 AHA/ACC Guideline for the Management of
Patients With Non–ST-Elevation Acute Coronary
Syndromes [26]
This guideline deals with CMR in two scenarios. First,
to determine early invasive versus ischemia-guided strat-
egy in patients with NSTEMI, the guideline mentions
that - among other factors – “noninvasive stress test find-
ings, including magnetic resonance imaging, may aid in
the identification of high-risk patients who could benefit
from an invasive strategy” (page 28). Second, in patients
presenting as NSTEMI but having angiographically normal
coronary arteries, the guideline mentions that “Myocarditis
may present with electrocardiographic and biomarker
findings similar to ACS and can be distinguished by mag-
netic resonance imaging” (page 49). Furthermore, the rec-
ommendation to use CMR to assess the presence of stress
(Takotsubo) cardiomyopathy is given (Table 11).
 2014 AHA/ACC/HRS Guideline for the
Management of Patients With Atrial Fibrillation [27]
CMR is mentioned in the text in the chapter “Mecha-
nisms of atrial fibrillation and pathophysiology / Atrial
structural abnormalities”: “Late gadolinium-enhancement
magnetic resonance imaging is used to image and quantitate
atrial fibrosis noninvasively. Human studies show a strong
correlation between regions of low voltage on electroanato-
mic mapping and areas of late enhancement on magnetic
resonance imaging. Preliminary results suggest that the se-
verity of atrial fibrosis correlates with the risk of stroke and
decreased response to catheter ablation” (page 9–10).
Table 10 Recommendations for CMR for risk stratification and follow-up in stable coronary artery disease
Classa Levelb Page
Resting imaging to assess cardiac structure and function
Echocardiography, radionuclide imaging, CMR, and cardiac CT are not recommended for routine assessment of LV
function in patients with a normal ECG, no history of myocardial infarction, no symptoms or signs suggestive of
heart failure, and no complex ventricular arrhythmias.
III C 29
Routine reassessment (<1 year) of LV function with technologies such as echocardiography, radionuclide imaging,
CMR, or cardiac CT is not recommended in patients with no change in clinical status and for whom no change in
therapy is contemplated.
III C 31
Risk assessment in patients able to exercise
CMR with pharmacological stress is reasonable for risk assessment in patients with stable ischemic heart disease
who are able to exercise to an adequate workload but have an uninterpretable ECG.
IIa B 30
Pharmacological stress imaging (nuclear MPI, echocardiography, or CMR) or CCTA is not recommended for risk
assessment in patients with stable ischemic heart disease who are able to exercise to an adequate workload and
have an interpretable ECG.
III C 30
Risk assessment in patients unable to exercise
Pharmacological stress CMR is reasonable for risk assessment in patients with stable ischemic heart disease who
are unable to exercise to an adequate workload regardless of interpretability of ECG.
IIa B 30
Risk assessment regardless of patients’ ability to exercise
Either exercise or pharmacological stress with imaging (nuclear MPI, echocardiography, or CMR) is recommended
for risk assessment in patients with stable ischemic heart disease, who are being considered for revascularization
of known coronary stenosis of unclear physiological significance.
I B 31
aClass of recommendation
bLevel of evidence
Table 11 Recommendations for CMR in NSTEMI with angiographically normal coronary arteries
Stress (Takotsubo) cardiomyopathy Classa Levelb Page
Imaging with ventriculography, echocardiography, or magnetic resonance imaging should be performed to confirm or exclude
the diagnosis of stress (Takotsubo) cardiomyopathy.
I B 49
aClass of recommendation
bLevel of evidence
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 2013 AHA/ACC/TOS Guideline for the Management
of Overweight and Obesity in Adults [28]
CMR is not mentioned in this guideline.
 2013 AHA/ACC Guideline on Lifestyle Management
to Reduce Cardiovascular Risk [29]
CMR is not mentioned in this guideline.
 2013 ACC/AHA Guideline on the Treatment of
Blood Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adults [30]
CMR is not mentioned in this guideline.
 2013 ACC/AHA Guideline on the Assessment of
Cardiovascular Risk [31]
CMR is not mentioned in this guideline.
 2012 ACCF/AHA/HRS Focused Update
Incorporated Into the ACCF/AHA/HRS 2008
Guidelines for Device-Based Therapy of Cardiac
Rhythm Abnormalities [9]
 2008 ACC/AHA/HRS Guidelines for Device-Based
Therapy of Cardiac Rhythm Abnormalities [32]
In both issues, CMR is mentioned once in the text as
a diagnostic tool to detect non-compaction of the left
ventricle (page 36).
 2011 ACCF/AHA Guideline for the Diagnosis and
Treatment of Hypertrophic Cardiomyopathy [33]
This guideline includes CMR in several text passages
as well as in specific recommendations for both diagno-
sis and risk stratification.
“The clinical diagnosis of HCM is conventionally made
with cardiac imaging, at present most commonly with 2-
dimensional echocardiography and increasingly with
CMR” (page 10). “In terms of LV wall-thickness mea-
surements, CMR is now used with increasing frequency,
and the writing group presumes that data with this latter
modality will increasingly emerge” (page 6). “Compared
with other noninvasive cardiac imaging modalities, CMR
provides superior spatial resolution with sharp contrast
between blood and myocardium, as well as complete
tomographic imaging of the entire LV myocardium and
therefore the opportunity to more accurately
characterize the presence, distribution, and extent of LV
hypertrophy in HCM” (page 14). “There remain patients
in whom the diagnosis of HCM is suspected but the
echocardiogram is inconclusive, mostly because of
suboptimal imaging from poor acoustic windows or
when hypertrophy is localized to regions of the LV myo-
cardium not well visualized by echocardiography... (pre-
dominantly anterolateral wall... or confined to the
apex)”. (page 15). “Similarly, in the subgroup of patients
with HCM who develop apical aneurysms, CMR can
more readily detect the presence of an aneurysm” (page
15). Therefore, CMR is also mentioned as a diagnostic
tool for HCM screening (page 11). Finally, other diseases
may have overlapping phenotypes. CMR with LGE con-
tributes to differentiate various forms of LV hypertrophy,
like HCM, Anderson-Fabry disease or cardiac amyloid-
osis (page 15). Table 12 summarizes the specific recom-
mendations for the use of CMR in HCM.
In addition to its diagnostic value, the use of CMR for
risk stratification in HCM is also discussed in the guide-
line. “Patients with HCM with evidence of LGE on CMR
imaging tend to have more markers of risk of sudden
cardiac death, such as non-sustained VT, than patients
without LGE” (page 15). It is a plausible and attractive
concept that areas of LGE... could represent a substrate
for the generation of malignant ventricular tachyarrhyth-
mias in HCM and thus a marker for risk of SCD. Several
studies have addressed this issue and have reported ei-
ther trends in such a direction or significant associations
between the presence of LGE ... and cardiac outcome
events. “However, there is insufficient evidence at this
time to support a significant association between the ex-
tent of LGE and outcome. ... Nonetheless, the present
cross-data would support a potential role of ... LGE as
an arbitrator to consider in clinical decision making for
primary prevention ICDs in patients in whom high-risk
status for sudden cardiac death remains uncertain
after assessment of conventional risk factors” (page
15). This assessment is reflected in a specific recom-
mendation (Table 12).
Finally, as HCM is regarded as a complex disease
entity, the writing committee emphasizes establishing
clinical excellence centers, including access to CMR
imaging (page 8).
 2011 ACCF/AHA Guideline for Coronary Artery
Bypass Graft Surgery [34]
CMR is not mentioned in this guideline.
 2011 AHA/ACCF Secondary Prevention and Risk
Reduction Therapy for Patients With Coronary and
Other Atherosclerotic Vascular Disease: 2011 Update [13]
 2006 AHA/ACC Guidelines for Secondary
Prevention for Patients With Coronary and Other
Atherosclerotic Vascular Disease: 2006 Update [14]
CMR is not mentioned in these guideline updates.
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 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/
CNS/ SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on
the Management of Patients With Extracranial
Carotid and Vertebral Artery [20]
The guideline contains several specific recommenda-
tions for the use of MR angiography to assess both ca-
rotid and vertebral arteries (Table 13). In addition, the
strength and limitations of MRA are described in detail.
Among other aspects, the NASCET stenosis grade based
on angiographic criteria corresponds well to sonography,
CT angiography and MR angiography, although the lat-
ter may overestimate the severity of stenosis (page 17). It
is also stated that patients with a high pretest probability
of disease may be examined initially by MR angiography
or CT angiography to more completely evaluate the
Table 12 Recommendations for CMR in HCM
Classa Levelb Page
CMR for the diagnosis of HCM
CMR imaging is indicated in patients with suspected HCM when echocardiography is inconclusive for diagnosis. I B 14
CMR imaging is indicated in patients with known HCM when additional information that may have an impact on
management or decision making regarding invasive management, such as magnitude and distribution of hypertrophy or
anatomy of the mitral valve apparatus or papillary muscles, is not adequately defined with echocardiography.
I B 14
CMR imaging is reasonable in patients with HCM to define apical hypertrophy and/or aneurysm if echocardiography is
inconclusive.
IIa B 14
CMR imaging may be considered in patients with LV hypertrophy and the suspicion of alternative diagnoses to HCM,
including cardiac amyloidosis, Fabry disease, and genetic phenocopies such as LAMP2 cardiomyopathy.
IIb C 14
CMR for risk stratification in HCM
In selected patients with known HCM, when SCD risk stratification is inconclusive after documentation of the conventional
risk factors, CMR imaging with assessment of late gadolinium enhancement (LGE) may be considered in resolving clinical
decision making.
IIb C 14
The usefulness of the following potential SCD risk modifiers is unclear but might be considered in selected patients with
HCM for whom risk remains borderline after documentation of conventional risk factors: CMR imaging with LGE.
IIb C 27
aClass of recommendation
bLevel of evidence
Table 13 Recommendations for MR in carotid and vertebral artery disease
Classa Levelb Page
Carotid artery
In patients with acute, focal ischemic neurological symptoms corresponding to the territory supplied by the left or right
internal carotid artery, magnetic resonance angiography (MRA) or computed tomography angiography (CTA) is indicated to
detect carotid stenosis when sonography either cannot be obtained or yields equivocal or otherwise nondiagnostic results.
I C 15
When an extracranial source of ischemia is not identified in patients with transient retinal or hemispheric neurological
symptoms of suspected ischemic origin, CTA, MRA, or selective cerebral angiography can be useful to search for intracranial
vascular disease.
IIa C 15
When the results of initial noninvasive imaging are inconclusive, additional examination by use of another imaging method
is reasonable. In candidates for revascularization, MRA or CTA can be useful when results of carotid duplex ultrasonography
are equivocal or indeterminate.
IIa C 15
When intervention for significant carotid stenosis detected by carotid duplex ultrasonography is planned, MRA, CTA, or
catheter-based contrast angiography can be useful to evaluate the severity of stenosis and to identify intrathoracic or intra-
cranial vascular lesions that are not adequately assessed by duplex ultrasonography.
IIa C 15
MRA without contrast is reasonable to assess the extent of disease in patients with symptomatic carotid atherosclerosis and
renal insufficiency or extensive vascular calcification.
IIa C 15
When complete carotid arterial occlusion is suggested by duplex ultrasonography, MRA, or CTA in patients with retinal or
hemispheric neurological symptoms of suspected ischemic origin, catheter-based contrast angiography may be considered
to determine whether the arterial lumen is sufficiently patent to permit carotid revascularization.
IIb C 15
Vertebral artery
Noninvasive imaging by CTA or MRA for detection of vertebral artery disease should be part of the initial evaluation of
patients with neurological symptoms referable to the posterior circulation and those with subclavian steal syndrome.
I C 47
In patients whose symptoms suggest posterior cerebral or cerebellar ischemia, MRA or CTA is recommended rather than
ultrasound imaging for evaluation of the vertebral arteries.
I C 47
Contrast-enhanced CTA, MRA, and catheter-based contrast angiography are useful for diagnosis of cervical artery dissection. I C 52
aClass of recommendation
bLevel of evidence
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cerebral vessels distal to the aortic arch, because sono-
graphic imaging alone does not provide assessment of
intrathoracic or intracranial lesions beyond the limited
range of the ultrasound probe (page 21). After carotid
stenting, imaging by CT angiography or MR angiography
may also be helpful for surveillance, particularly “when
Doppler interrogation is difficult because of a superior
anatomic location of the region of interest” (page 41).
 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/
STS/SVM Guidelines for the Diagnosis and
Management of Patients With Thoracic Aortic
Disease [21]
The guideline includes a chapter explaining the princi-
ples, strength and limitations of CMR to assess the thor-
acic aorta (page 17). CMR “has been shown to be very
accurate in the diagnosis of thoracic aortic disease, with
sensitivities and specificities that are equivalent to or
may exceed those for CT and TEE” (page 17). “Advan-
tages of CMR include the ability to identify anatomic
variants of aortic dissection (intramural hematoma,
penetrating aortic ulceration), assess branch artery in-
volvement, and diagnose aortic valve pathology and left
ventricular dysfunction without exposing the patient to
either radiation or iodinated contrast” (page 17).
Throughout the text, the use of CMR in different clinical
scenarios and pathologies is described and evaluated.
CMR is an integral part of a number of diagnostic path-
ways illustrated in various figures, e.g., the aortic dissec-
tion pathway (figure 25 in the guideline, page 45) and
the ascending aortic aneurysm pathway (figure 31 in the
guideline, page 56). In addition, CMR is recommended
for surveillance of stable and moderate thoracic aortic
aneurysms (page 76), as well as for follow-up of aortic
pathologies after repair or treatment (page 77, table 17 in
the guideline). Finally, there are a number of specific
recommendations on the use of CMR in patients with
thoracic aortic disease (Table 14).
 2010 ACCF/AHA Guideline for Assessment of
Cardiovascular Risk in Asymptomatic Adults [18]
The use of CMR for the assessment of arterial stiffness
by quantifying pulse wave velocity is mentioned. How-
ever, CMR “is more costly and therefore is typically not
used for testing in asymptomatic persons” (page 23).
CMR is described in detail as a method for “detection
and quantification of atherosclerosis. ... Examination of
plaque under different contrast weighting ... allows
characterization of individual plaque components, in-
cluding lipid-rich necrotic core, fibrous cap status,
Table 14 Recommendations for CMR in thoracic aortic disease
Classa Levelb Page
Recommendations for acute thoracic aortic disease
Urgent and definitive imaging of the aorta using transesophageal echocardiogram, computed tomographic imaging, or
magnetic resonance imaging is recommended to identify or exclude thoracic aortic dissection in patients at high risk for the
disease by initial screening.
I B 43
Recommendations for Takayasu arteritis and giant cell arteritis
The initial evaluation of Takayasu arteritis or giant cell arteritis should include thoracic aorta and branch vessel computed
tomographic imaging or magnetic resonance imaging to inves- tigate the possibility of aneurysm or occlusive disease in
these vessels.
I C 28
Recommendations for aortic arch aneurysms
For patients with isolated aortic arch aneurysms less than 4.0 cm in diameter, it is reasonable to reimage using computed
tomographic imaging or magnetic resonance imaging, at 12- month intervals, to detect enlargement of the aneurysm.
IIa C 58
For patients with isolated aortic arch aneurysms 4.0 cm or greater in diameter, it is reasonable to reimage using computed
tomographic imaging or magnetic resonance imaging, at 6-month intervals, to detect enlargement of the aneurysm.
IIa C 58
Recommendations for chronic aortic diseases in pregnancy
For imaging of pregnant women with aortic arch, descending, or abdominal aortic dilatation, magnetic resonance imaging
(without gadolinium) is recommended over computed tomographic imaging to avoid exposing both the mother and fetus
to ionizing radiation. Transesophageal echocardiogram is an option for imaging of the thoracic aorta.
I C 64
Recommendations for surveillance of thoracic aortic disease or previously repaired patients
Computed tomographic imaging or magnetic resonance imaging of the thoracic aorta is reasonable after a Type A or B
aortic dissection or after prophylactic repair of the aortic root/ ascending aorta.
IIa C 76
Computed tomographic imaging or magnetic resonance imaging of the aorta is reasonable at 1, 3, 6, and 12 months
postdissection and, if stable, annually thereafter so that any threatening enlargement can be detected in a timely fashion.
IIa C 76
If a thoracic aortic aneurysm is only moderate in size and remains relatively stable over time, magnetic resonance imaging
instead of computed tomographic imaging is reasonable to minimize the patient’s radiation exposure.
IIa C 76
aClass of recommendation
bLevel of evidence
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hemorrhage, and calcification. ... It is recommended that
additional large-scale multicenter trials be conducted to
evaluate the possibility of using CMR in the detection of
atherosclerosis in asymptomatic patients” (page 32). Yet,
despite the potential of CMR for atherosclerotic plaque
characterization, it is currently not recommended for
screening asymptomatic subjects (Table 15).
 2008 ACC/AHA Guidelines for the Management of
Adults With Congenital Heart Disease (ACHD) [19]
In general, “cardiac MRI to assess ventricular anatomy
and function, dimensions, myocardial perfusion, and is-
chemia in adults with unoperated or operated CHD is
regarded as helpful” (page 29). CMR is also recommended
as an integral part of regional ACHD centers (page 11,
table 2 in the guideline). The guideline contains numerous
text passages regarding the use of CMR in specific con-
genital heart diseases and clinical scenarios, such as ven-
tricular septal defect (page 37), atrial septal defect (page
40), supravalvular aortic stenosis (page 51), and right ven-
tricular outflow tract obstruction (page 56). To provide an
example, the recommendations regarding aortic coarcta-
tion state that “MRI … with 3-dimensional reconstruction
identifies the precise location and anatomy of the coarcta-
tion and entire aorta, as well as collateral vessels. … Mag-
netic resonance angiography may also be useful to
quantify collateral flow.” (page 53). In addition, a number
of specific recommendations are made (Table 16).
 2006 ACC/AHA/ESC Guidelines for Management
of Patients With Ventricular Arrhythmias and the
Prevention of Sudden Cardiac Death [35]
The guideline dedicates a paragraph to the strength of
CMR “to evaluate both the structure and function of the
beating heart. The excellent image resolution obtained
with current techniques allows for the accurate quantifi-
cation of chamber volumes, LV mass, and ventricular
function. This is of particular value in patients with sus-
pected arrhythmogenic RV cardiomyopathy (ARVC), in
whom MRI provides excellent assessment of RV size,
function, and regional wall motion and, importantly,
may allow the detection of fatty infiltration within the
RV myocardium. … Cardiac MRI increasingly is being
applied and validated for the detection of ischemia (ad-
enosine stress perfusion and dobutamine stress wall mo-
tion studies) and the detection and quantification of
infarction/fibrosis, a substrate for VT.” In addition,
CMR is mentioned to detect cardiac involvement in sar-
coidosis (page 41), “to be helpful in assessing extent of
disease and predicting sudden cardiac death” (page 48),
in hypertrophic cardiomyopathy, and “for the evaluation
of patients with ventricular tachycardia arising from the
RV in the absence of defined abnormalities on conven-
tional testing particularly to exclude ARVC” (page 59).
Finally, the guideline contains one specific recommenda-
tion for CMR for accurate assessment of LV and RV
function and evaluation of structural changes (Table 17).
Discussion
This study demonstrates that CMR is mentioned in the
majority of the AHA/ACC guidelines (66.7%) and that
50% of the AHA/ACC guidelines contain a total of 65
specific recommendations for when and how to use
CMR. When analyzing the AHA/ACC guidelines in de-
tail, some interesting aspects arise:
First, a look at the specific recommendations reveals
that the indication category with the largest number of
specific recommendations is vascular imaging. This is
probably related to the fact that vascular imaging (MR
angiography) is one of the most established CMR tech-
niques. It is also worth noting that there is significant
heterogeneity across the guidelines regarding whether a
particular topic is only mentioned in the text, versus be-
ing included as a specific recommendation and assigned
a class of recommendation and a level of evidence.
Hence, to simply correlate the absolute number of spe-
cific recommendations with the importance of CMR
across guideline documents may be flawed. Nevertheless,
the large number of specific recommendations in the
vascular disease category certainly underlines the well-
defined role of CMR and MR angiography. This has also
been reflected in the ESC guideline analysis, which
showed in total 17 specific recommendations in the vas-
cular category [3].
The category with the second highest number of rec-
ommendations is congenital heart disease. Patients with
congenital heart disease are monitored and treated
mostly in dedicated centers. The prevalence in CMR in
AHA/ACC guidelines for congenital heart disease un-
derscores the fact that CMR is commonly utilized in this
population both in the preoperative state and during pa-
tient follow-up.
Regarding CMR myocardial stress testing, only eight
specific recommendations exist. In relation to the
Table 15 Recommendations for CMR for assessment of cardiovascular risk in asymptomatic adults
Recommendation for imaging of plaque Classa Levelb Page
MRI for detection of vascular plaque is not recommended for cardiovascular risk assessment in asymptomatic adults. III C 32
aClass of recommendation
bLevel of evidence
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Table 16 Recommendations for CMR for management of adults with congenital heart disease
Classa Levelb Page
Recommendations for adults with congenital heart disease (ACHD)
Diagnostic and interventional procedures, including imaging (ie, echocardiography, MRI, or CT, advanced
cardiac catheterization, and electrophysiology procedures for adults with complex and moderate CHD
should be performed in a regional ACHD center with appropriate experience in CHD and in a laboratory
with appropriate personnel and equipment. Personnel performing such procedures should work as part of
a team with expertise in the surgical and transcatheter management of patients with CHD.
I C 12–13
Bicuspid aortic valve disease
MRI/CT can be beneficial to add important information about the anatomy of the thoracic aorta. IIa C 45
MRI may be beneficial in quantifying aortic regurgitation when other data are ambiguous or borderline. IIb C 45
Supravalvular aortic stenosis
TTE and/or TEE with Doppler and either MRI or CT should be performed to assess the anatomy of the LVOT,
the ascending aorta, coronary artery anatomy and flow, and main and branch pulmonary artery anatomy and flow.
I C 50
Aortic coarctation
Every patient with coarctation (repaired or not) should have at least 1 cardiovascular MRI or CT scan for
complete evaluation of the thoracic aorta and intracranial vessels.
I B 52
Evaluation of the coarctation repair site by MRI/CT should be performed at intervals of 5 years or less,
depending on the specific anatomic findings before and after repair.
I C 53
Supravalvular, branch, and peripheral pulmonary stenosis
Patients with suspected supravalvular, branch, or peripheral pulmonary stenosis should have baseline
imaging with echocardiography-Doppler plus 1 of the following: MRI angiography, CT angiography, or
contrast angiography.
I C 61
Congenital coronary anomalies of ectopic arterial origin
CT or MRA is useful as the initial screening method in centers with expertise in such imaging. I B 65
Coronary arteriovenous fistula
If a continuous murmur is present, its origin should be defined either by echocardiography, MRI, CT
angiography, or cardiac catheterization.
I C 67
Congenital heart disease and pulmonary arterial hypertension
The evaluation of all ACHD patients with suspected pulmonary arterial hypertension should include
noninvasive assessment of cardiovascular anatomy and potential shunting, as detailed below:
Diagnostic cardiovascular imaging via TTE, TEE, MRI, or CT as appropriate.
I C 70
After repaired of tetralogy of Fallot
Patients with tetralogy of Fallot should have echocardiographic examinations and/or MRIs performed
by staff with expertise in ACHD.
I C 73
Dextro-Transposition of the great arteries
Additional imaging with TEE, CT, or MRI, as appropriate, should be performed in a regional ACHD center to
evaluate the great arteries and veins, as well as ventricular function, in patients with prior atrial baffle
repair of d-TGA.
I B 80
Periodic MRI or CT can be considered appropriate to evaluate the anatomy and hemodynamics in more
detail in patients with prior arterial switch operation.
IIa C 80
Congenitally corrected transposition of the great arteries
Echocardiography-Doppler study and/or MRI should be performed yearly or at least every other year by
staff trained in imaging complex CHD.
I C 87
The following diagnostic evaluations are recommended for patients with congenitally corrected transposition
of the great arteries: ECG, chest x-ray, echocardiography-Doppler study, MRI, exercise testing.
I C 87
In patients with prior repair of congenitally corrected transposition of the great arteries, echocardiography-
Doppler study and/or MRI should be performed yearly or at least every other year by staff trained in
imaging complex CHD.
I C 89
After Fontan Procedure
All patients with prior Fontan type of repair should have periodic echocardiographic and/or magnetic resonance
examinations performed by staff with expertise in ACHD.
I C 97
aClass of recommendation
bLevel of evidence
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number of guidelines dealing with coronary artery dis-
ease (guidelines for STEMI, NSTEMI and stable coron-
ary artery disease), the evidence proving the diagnostic
accuracy for CMR stress testing to detect coronary ar-
tery disease [2], and the dominance of coronary artery
disease in clinical routine, this number suggests an un-
derrepresentation of CMR stress testing. Conversely,
CMR stress testing has a greater presence in the ESC
guidelines where it is treated as equivalent with other
modalities such as stress echocardiography and nuclear
perfusion studies, ending up in a total of 28 specific rec-
ommendations [3]. With new data recently published,
such as the CE-MARC 2 trial in 2016 that showed that
CMR stress testing contributes to a lower rate of “un-
necessary” invasive coronary angiographies [2], the role
of CMR stress testing may increase in future editions of
the AHA/ACC guidelines. The limited representation of
CMR to assess viability to guide revascularization with
only 3 specific recommendations can be interpreted in a
similar sense.
Finally, there are only 6 specific recommendations
regarding cardiomyopathies, all of which are part of the
hypertrophic cardiomyopathy guidelines – a similar
pattern as in the ESC guidelines [3]. In contrary, the
evaluation of patients with known or suspected cardio-
myopathy is the second largest indication group in clin-
ical CMR in Europe, as expressed in the EuroCMR
registry that included more than 27,000 patients [1].
This discrepancy may be attributed to the lack of a
guideline covering cardiomyopathies in general. In case
such a paper would be generated, there may be add-
itional recommendations in favor of CMR, e.g., for as-
sessment of arrhythmogenic ventricular cardiomyopathy,
for risk stratification and differential diagnosis in dilated
cardiomyopathy, for the diagnosis of non-compaction
cardiomyopathy, and for diseases causing restrictive
types of cardiomyopathies.
The use of CMR to assess myocarditis represents an-
other discrepancy between representation in the AHA/
ACC guidelines versus the level of evidence and clinical
utilization in practice. Myocarditis is one of the most
frequent indications for CMR in Europe [36] and the
evidence for its diagnostic benefit is proven [37, 38]. In
contrast, there is no single specific recommendation for
CMR to assess myocarditis in the AHA/ACC guidelines.
Only once in the context of differentiating acute coron-
ary syndrome is CMR to assess myocarditis mentioned
[26]. This might be attributed to the lack of a focused
guideline regarding inflammatory heart diseases. In this
regard, the AHA/ACC guidelines resemble the ESC
guidelines; only one ESC guideline (concerning patients
with ventricular arrhythmias) contains a single specific
recommendation to perform CMR for risk stratification
in inflammatory heart disease [39].
When analyzing those guidelines that cover overlap-
ping topics (e.g., ischemic heart disease), there exists
considerable heterogeneity in how they deal with similar
topics. For example, the 2014 guideline on stable
coronary artery disease contains several specific recom-
mendations for CMR stress testing. On the other hand,
similar chapters in the guideline on NSTEMI or assess-
ment of ventricular arrhythmias contain no specific rec-
ommendations for stress CMR. This may reflect the
different publication dates, as the clinical evidence and
utilization of stress CMR have continued to grow. In
addition, a high degree of coordination is required to
synchronize recommendations for indications that ap-
pear in multiple guidelines.
When looking at those guidelines that do not mention
CMR at all, it seems understandable that the guidelines
dealing with “supraventricular tachycardia”, “over-
weight”, “lifestyle management” and “blood cholesterol”
would not include recommendations for CMR. In con-
trast it is rather surprising - based on the topic and the
common indications for CMR - that the AHA/ACC
guidelines dealing with “STEMI”, “assessment of cardio-
vascular risk”, “secondary prevention for patients with
coronary vascular disease” and “CABG” do not mention
CMR at all. In comparison, the ESC-STEMI guideline
from 2012 contains 2 specific recommendations (for as-
sessment of infarct size and resting LV function; for is-
chemia and viability).
Four AHA/ACC guidelines mention CMR in the text
without including specific recommendations (“before
noncardiac surgery”, “atrial fibrillation”, “percutanoues
coronary intervention”, “device therapy”). In future edi-
tions, some text passages may be accompanied by spe-
cific recommendations. On the other hand, the atrial
fibrillation guideline from 2014 mentions late enhance-
ment imaging of atrial fibrosis to predict therapeutic
success [27]. Even though there is growing evidence for
this application [40], its use within the CMR society is
actually restricted to a small group. Thus, despite the
intention to place CMR in the guidelines where the
Table 17 Recommendations for CMR for patients with ventricular arrhythmias and the prevention of sudden cardiac death
Recommendations for CMR for patients with ventricular arrhythmias and the prevention of sudden cardiac death Classa Levelb Page
MRI, cardiac computed tomography (CT), or radionuclide angiography can be useful in patients with ventricular arrhythmias
when echocardiography does not provide accurate assessment of LV and RV function and/or evaluation of structural changes.
IIa B 19
aClass of recommendation
bLevel of evidence
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evidence supports this, modesty should also be part of
the strategy to avoid the dilemma of creating non-
accomplishable expectations.
Limitations of the study
This summary is not intended to provide a comparison
of the various imaging modalities in the AHA/ACC
guidelines, but is rather aimed at only describing the role
of CMR. Its character is more descriptive than analytical,
and its layout designed to allow the reader to easily lo-
cate CMR recommendations in the guidelines, rather
than to serve as a scientific meta-analysis. Additional
analyses, e.g., focusing on myocardial stress testing in all
guidelines regarding all available methods, will be sub-
ject of future studies. Furthermore, there are guidelines,
where every detail is represented in a specific recom-
mendation, and others, where only general recommen-
dations are made; this leads to significant heterogeneity
in the number of recommendations included in different
guidelines. Naturally, the composition of the writing
groups influences the content of the guidelines, and
therefore the representation of CMR. However, no sys-
tematic data are available regarding the inclusion of
CMR experts in the writing groups and therefore this
potential influencing factor cannot be evaluated. An-
other factor influencing the representation of CMR in
the guidelines could be the length of time it takes to
generate guideline documents. It can be a 5-year process
from the time of conception to publication and thus
some aspects may be out of date by the time of publica-
tion. Finally, a systematic and scientific comparison of
the AHA/ACC and the ESC guidelines is difficult, as
most of the corresponding guidelines were not published
at the same time, and many topics are not covered by
guidelines of both organizations. Hence, the comparative
assessments that are included must be viewed with this
limitation in mind.
Conclusions
CMR is represented in two thirds of the AHA/ACC
guidelines, and these guidelines contain many recom-
mendations in favor of the use of CMR in specific sce-
narios. In general, the representation of CMR is
heterogeneous throughout the guidelines, with some
topics (such as CMR in vascular disease and congenital
heart disease) containing numerous recommendations for
CMR, and others (such as those dealing with coronary ar-
tery disease) including few recommendations relative to
the broad topic-related evidence. Although a direct com-
parison of the AHA/ACC to the ESC guidelines is difficult
due to heterogeneous characteristics of both sets, CMR
appears to be less represented in the AHA/ACC guide-
lines, in particular in coronary artery disease.
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